---
id: aan-migraine-prevention-update-2024
title: "AAN Practice Guideline Update: Preventive Migraine Treatment in Adults"
short_title: "Migraine Prevention Update - Adults"
organization: American Academy of Neurology
country: United States
url: https://www.aan.com/Guidelines/Home/GuidelineDetail/1260
specialty: neurology
guideline_type: clinical-practice
evidence_system: aan-grade
conditions:
  - Migraine
  - Chronic Migraine
  - Episodic Migraine
tags:
  - migraine
  - headache
  - preventive therapy
  - CGRP inhibitors
  - botulinum toxin
publication_date: 2024-05-01
previous_version_date: 2012-04-24
status: current
supersedes: aan-migraine-prevention-2012
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides updated recommendations for the preventive treatment of migraine in adults, incorporating new evidence for anti-CGRP therapies and other emerging treatments.

## Key Recommendations

### When to Consider Prevention
- ≥4 headache days per month
- Significant disability despite acute treatment
- Contraindication to acute medications
- Medication overuse or risk thereof

### Oral Preventive Medications
**Level A Evidence:**
- Topiramate 50-100mg/day
- Divalproex sodium/valproate 500-1000mg/day
- Propranolol 80-240mg/day
- Metoprolol 50-200mg/day

**Level B Evidence:**
- Amitriptyline 25-150mg/day
- Venlafaxine 75-150mg/day
- Candesartan 16mg/day

### CGRP Pathway Therapies
**Monoclonal Antibodies (Level A):**
- Erenumab 70-140mg monthly
- Fremanezumab 225mg monthly or 675mg quarterly
- Galcanezumab 120mg monthly (240mg loading)
- Eptinezumab 100-300mg IV quarterly

**Oral Gepants:**
- Atogepant 60mg daily
- Rimegepant 75mg every other day

### OnabotulinumtoxinA
- Indicated for chronic migraine (≥15 days/month)
- 155-195 units every 12 weeks
- PREEMPT injection protocol

### Neuromodulation
- Non-invasive vagus nerve stimulation
- External trigeminal nerve stimulation
- Remote electrical neuromodulation

### Treatment Selection
- Consider patient comorbidities and preferences
- Trial period: 2-3 months at therapeutic dose
- Combination therapy may be needed
- Reassess need after 6-12 months of good control
